Type 2 Diabetes Mellitus in India: Diagnostic Tests, Treatment Protocols and Local Drug Availability
{“title”:”Type 2 Diabetes Mellitus in India: Diagnostic Tests, Treatment Protocols and Local Drug Availability”,”excerpt”:”Comprehensive guide to diagnosing and managing Type 2 Diabetes Mellitus in India, covering standard laboratory tests, first‑line medications, surgical options and culturally tailored diet plans.”,”content_html”:”n
India is experiencing a rapid rise in non‑communicable diseases, with Type 2 Diabetes Mellitus (T2DM) being the most prevalent. The Indian population presents unique challenges such as early onset, genetic predisposition, and dietary habits rich in refined carbohydrates. This article provides a detailed, evidence‑based approach for clinicians practicing in India, covering:n
n
- n
- Standard diagnostic work‑up (screening, confirmation and monitoring)n
- First‑line pharmacotherapy (oral agents and insulin) with emphasis on drugs approved by the Central Drugs Standard Control Organization (CDSCO)n
- Advanced therapeutic options including GLP‑1 receptor agonists, SGLT2 inhibitors and bariatric surgeryn
- Local drug availability, generic alternatives and cost‑effective regimensn
- Dietary recommendations tailored to Indian cuisine and socioeconomic contextn
n
1. Diagnostic Work‑Up in India
n
Diagnosis of T2DM follows the American Diabetes Association (ADA) criteria, which are also accepted by the Indian Council of Medical Research (ICMR). All patients presenting with classic symptoms or risk factors should undergo the following tests:n
n
1.1 Screening Tests (for high‑risk individuals)
n
- n
- Random Plasma Glucose (RPG): RPG >200 mg/dL (11.1 mmol/L) with symptoms confirms diabetes.n
- Fasting Plasma Glucose (FPG): FPG ≥126 mg/dL (7.0 mmol/L) on two separate occasions confirms diabetes.n
- HbA1c: HbA1c ≥6.5% (48 mmol/mol) on two occasions confirms diabetes.n
n
1.2 Confirmatory Tests (for all suspected cases)
n
- n
- Repeat FPG and HbA1c if initial values are borderline.n
- Oral Glucose Tolerance Test (OGTT) – 75 g glucose load; 2‑hour plasma glucose ≥200 mg/dL confirms diabetes.n
n
1.3 Baseline Investigations (upon diagnosis)
n
- n
- Renal function: Serum creatinine, eGFR (CKD‑EPI formula).n
- Urine albumin: Albumin-to-creatinine ratio (ACR).n
- Lipid profile: Total cholesterol, LDL, HDL, triglycerides.n
- Hepatitis B surface antigen (HBsAg) – especially in patients with elevated ALT.n
- Blood pressure measurement (average of two readings).n
n
1.4 Monitoring Schedule (per Indian guidelines)
n
- n
- HbA1c: Every 3 months if <7.0%; every 6 months if ≥7.0%.n
- FPG/PPG (post‑prandial glucose) weekly for the first month of therapy, then monthly.n
- Lipid profile annually or more frequently if on statins.n
- Liver and renal function tests quarterly for patients on metformin or insulin.n
n
2. Pharmacotherapy – First‑Line and Step‑Up Regimens
n
2.1 Oral Anti‑Diabetic Drugs (OADs) Available in India
n
India has a robust supply of generic antidiabetic agents, many of which are cheaper than branded equivalents. The following table summarizes commonly prescribed OADs, their mechanisms, contraindications and local availability.n
n
| Drug Class | Common Drugs (Generic) | Mechanism of Action | Contraindications/Warnings |
|---|---|---|---|
| Biguanides | Metformin (Glucophage®) | Decrease hepatic gluconeogenesis, improve insulin sensitivity | Renal impairment (eGFR<30 ml/min), severe hepatic disease |
| Sulfonylureas | Glimepiride, Glipizide, Gliclazide | Stimulate pancreatic β‑cell insulin secretion | Renal or hepatic impairment, risk of hypoglycaemia in elderly |
| Thiazolidinediones (TZDs) | Pioglitazone, Rosiglitazone | Activate PPAR‑γ to improve insulin sensitivity | Heart failure, hepatic dysfunction, bladder cancer (rosiglitazone) |
| DPP‑4 Inhibitors | Sitagliptin, Vildagliptin, Saxagliptin | Inhibit DPP‑4 to increase GLP‑1 and GIP levels | Heart failure (saxagliptin), pancreatitis rare |
| SGLT2 Inhibitors | Dapagliflozin, Empagliflozin, Canagliflozin | Inhibit renal glucose reabsorption (SGLT2) | Renal impairment, genital infections |
| GLP‑1 Receptor Agonists | Liraglutide, Exenatide (short‑acting), Lixisenatide | Stimulate GLP‑1 receptors → ↑ insulin, ↓ glucagon | Nausea, pancreatitis risk, contraindicated in T2DM with prior medullary thyroid carcinoma |
| Insulin | Lantus® (glargine), Novorapid® (aspart) | Directly replace insulin deficiency | Hypoglycaemia, weight gain, injection site reactions |
| Combination OADs | Metformin + Sitagliptin, Metformin + Glimepiride | Synergistic effects; lower hypoglycaemia risk with metformin combinations | Same as individual components |
n
2.2 First‑Line Therapy (ADA/ICMR Guideline)
n
- n
- Metformin – 500 mg twice daily, titrate to 2000 mg/day as tolerated.n
- Consider adding a second agent if HbA1c >7.5% after 3 months.n
n
2.3 Step‑Up Options (if HbA1c >7% after 6 months)
n
- n
- Add a GLP‑1 RA (e.g., Liraglutide 0.6 mg SC daily) – benefits: weight loss, CV protection.n
- Switch to or add an SGLT2 inhibitor (e.g., Empagliflozin 10 mg PO daily) – benefits: renal and CV protection.n
- Consider a DPP‑4 inhibitor (e.g., Vildagliptin 50 mg PO twice daily) if patient prefers oral therapy.n
n
2.4 Insulin Regimens (when OADs fail)
n
- n
- Basal insulin: Glargine 10 units at bedtime; titrate by 2–4 units every 3 days.n
- Basal‑bolus: Add rapid‑acting insulin (Lispro or Aspart) before meals.n
- Fixed ratio combinations: Soluble insulin premixed (30/70) for patients with variable meal patterns.n
n
2.5 Local Drug Availability and Cost‑Effective Strategies
n
- n
- Generic metformin is available at ₹10–20 per